142 related articles for article (PubMed ID: 8336941)
41. Distance constraints and stereospecific alignment requirements characteristic of p53 DNA-binding consensus sequence homologies.
Cook JL; Ré RN; Giardina JF; Fontenot FE; Cheng DY; Alam J
Oncogene; 1995 Aug; 11(4):723-33. PubMed ID: 7651736
[TBL] [Abstract][Full Text] [Related]
42. p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2004 Aug; 64(15):5078-83. PubMed ID: 15289308
[TBL] [Abstract][Full Text] [Related]
43. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
44. [Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants].
Almazov VP; Morgunkova AA; Kalinin VN; Kopnin BP; Prasolov VS; Chumakov PM
Mol Biol (Mosk); 2002; 36(4):664-71. PubMed ID: 12173471
[TBL] [Abstract][Full Text] [Related]
45. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
46. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
47. Abrogation of p53-mediated transactivation by SV40 large T antigen.
Segawa K; Minowa A; Sugasawa K; Takano T; Hanaoka F
Oncogene; 1993 Mar; 8(3):543-8. PubMed ID: 8382354
[TBL] [Abstract][Full Text] [Related]
48. Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat.
Boehden GS; Baumann C; Siehler S; Wiesmüller L
Oncogene; 2005 Jun; 24(26):4183-92. PubMed ID: 15782112
[TBL] [Abstract][Full Text] [Related]
49. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
50. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
51. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes.
Thornborrow EC; Patel S; Mastropietro AE; Schwartzfarb EM; Manfredi JJ
Oncogene; 2002 Feb; 21(7):990-9. PubMed ID: 11850816
[TBL] [Abstract][Full Text] [Related]
52. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
Mirza A; Wu Q; Wang L; McClanahan T; Bishop WR; Gheyas F; Ding W; Hutchins B; Hockenberry T; Kirschmeier P; Greene JR; Liu S
Oncogene; 2003 Jun; 22(23):3645-54. PubMed ID: 12789273
[TBL] [Abstract][Full Text] [Related]
53. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
54. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype.
Frebourg T; Sadelain M; Ng YS; Kassel J; Friend SH
Cancer Res; 1994 Feb; 54(4):878-81. PubMed ID: 8313374
[TBL] [Abstract][Full Text] [Related]
55. The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its antiproliferation function.
Zhang W; Randhawa GS; Guo XY; Deisseroth AB
Cell Growth Differ; 1994 Jul; 5(7):705-10. PubMed ID: 7947385
[TBL] [Abstract][Full Text] [Related]
56. Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved.
Wang Y; Farmer G; Soussi T; Prives C
Oncogene; 1995 Feb; 10(4):779-84. PubMed ID: 7862457
[TBL] [Abstract][Full Text] [Related]
57. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.
Jagosova J; Pitrova L; Slovackova J; Ravcukova B; Smarda J; Smardova J
Int J Oncol; 2012 Sep; 41(3):1157-63. PubMed ID: 22710932
[TBL] [Abstract][Full Text] [Related]
58. A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors.
Lin SR; Yang YC; Jung JH; Tsai JH
DNA Cell Biol; 1996 Oct; 15(10):793-803. PubMed ID: 8892752
[TBL] [Abstract][Full Text] [Related]
59. A functional screen for germ line p53 mutations based on transcriptional activation.
Frebourg T; Barbier N; Kassel J; Ng YS; Romero P; Friend SH
Cancer Res; 1992 Dec; 52(24):6976-8. PubMed ID: 1458490
[TBL] [Abstract][Full Text] [Related]
60. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
Bargonetti J; Reynisdóttir I; Friedman PN; Prives C
Genes Dev; 1992 Oct; 6(10):1886-98. PubMed ID: 1398068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
